Who’s Winning the Race for a COVID-19 Vaccine?

Several companies — some publicly traded — have been working on a COVID-19 vaccine for months. Today, Wealth Daily contributor Samuel Taube takes a look at the current state of the race for a vaccine. Several companies — some publicly traded — have been working on a COVID-19 vaccine for months. Today, Wealth Daily contributor Samuel Taube takes a look at the current state of the race for a vaccine. [Wealth Daily logo] Who’s Winning the Race for a COVID-19 Vaccine? [Samuel Taube Photo] By [Samuel Taube]( Written Sep 05, 2020 It’s hard to believe that a year ago, COVID-19 didn’t have a name. In fact, we weren’t even aware of its existence until December. Yet today, the nascent disease has killed more than 840,000 people worldwide, more than 180,000 of whom lived in this country. And a number of biotech companies — including two publicly traded firms — are racing to develop the vaccine that will put it behind us. Which vaccine will make it to market first? Which works best? And how can investors help their development (and enrich themselves in the process)? To answer these questions, we’ve got to get to know the three leading vaccine candidates... Russia’s Untested Vaccine And before we get to the leading American and British vaccine candidates, we should probably discuss the Russian vaccine that has already been “approved” by the country’s government. Last month, Russia’s Ministry of Health issued a “registration certificate” for a vaccine called Sputnik V, developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow. The two-shot vaccine contains cold viruses that have been modified to carry the surface protein of the coronavirus. These modified viruses train the immune system to fight the coronavirus on its own. The vaccine supposedly confers two years of COVID-19 immunity to recipients. [YOU MISSED IT]( What happened!? You’ve missed the Paydirt 2020 Summit. If it was by mistake (or if something urgent came up) then I have some GOOD news. We’re going to hold the door open a little longer... We’ve put the entire video of the Paydirt 2020 Summit on a special “Rebroadcast” site. [Your Final Chance to See This Must-Watch Event]( But warning: it won’t be up for long. The gold market is moving so fast and spots are filling up so quickly that we’ll be disabling the site very soon. Please don’t miss this final chance to pull in OUTRAGEOUS gains on gold — click the link above. The certificate allows Sputnik V to be given to “a small number of citizens from vulnerable groups,” like frontline medical staff and elderly people. But it doesn’t allow the vaccine to be used widely until next year... because Russia hasn’t really tested it yet. At the time of writing, it had only been tested on 76 people. Hypothetically, that could be a non-issue. Gamelaya has successfully developed vaccines before without major safety hiccups. But the lack of testing is certainly risky, some would even say reckless. Back in 2007, the FDA halted trials of an experimental HIV vaccine that used the same technology — minor viruses modified to carry proteins from the target virus — after it found that the drug actually increased patients’ susceptibility to HIV. If Sputnik V backfires in a similar way, it could pour gasoline on the fire of the COVID-19 pandemic. With this in mind, biotech investors should ignore the news out of Russia until more substantive clinical trial data becomes available. Instead, focus on the western firms that are developing vaccines by the book. Moderna’s (NASDAQ: MRNA) Vaccine Candidate And among American firms, no one is further along than Moderna (NASDAQ: MRNA). The Massachusetts-based biotech company is developing a two-shot vaccine that uses messenger RNA (mRNA) to deliver viral genetic code to the patient’s immune cells, training them to recognize and fight the virus in the process. Moderna’s vaccine candidate was the first to enter human testing in the U.S., and it’s currently in a massive Phase 3 clinical trial with 30,000 participants. There is an element of risk to Moderna’s strategy; the mRNA technology its vaccine candidate uses is relatively new and has never successfully produced an approved vaccine before. But it’s in the last stage of testing and has appeared to be safe and effective so far. If Moderna wins first place in the vaccine race, its shareholders could benefit handsomely. The firm is currently worth less than $26 billion — a tiny market capitalization compared to the other two vaccine frontrunners... AstraZeneca’s (NYSE: AZN) Vaccine Candidate On the other side of the pond, AstraZeneca (NYSE: AZN) is also well into Phase 3 clinical trials for its vaccine candidate. The AstraZeneca vaccine uses similar technology to the untested Russian vaccine; it uses a modified carrier virus to deliver coronavirus proteins to the immune system so that it can start learning how to destroy them. But unlike the Russians, AstraZeneca is putting its vaccine through its paces when it comes to testing. A 30,000-subject Phase 3 trial began in the U.S. last month, and so far, the vaccine has successfully produced immune responses with only minor side effects. "Small Pill Could Save Millions of Lives" — Kevin O’Leary [kevin oleary shark tank]( Chronic diseases like alcoholism, opioid addiction, diabetes, and depression can be a death sentence for millions of sufferers. Regular treatments work only 30% of the time and can take years. Now the FDA has given the go-ahead to a small pill that wipes out these diseases with just one or two doses. And elite research institutions, like Johns Hopkins, Stanford, and Harvard, have replicated and confirmed the results. "Mr. Wonderful," Kevin O’Leary, has already invested millions. [Details here...]( How to Invest in a COVID-19 Vaccine Moderna, AstraZeneca, and Gamelaya aren’t the only firms developing COVID-19 vaccine candidates. Pfizer, Johnson & Johnson, Novavax, and a handful of Chinese firms are also working on shots for the virus, but they’re moving slower than the two firms we’ve discussed in this article. So which one should you buy? The safest answer is... both. The nice thing about both Moderna and AstraZeneca is that they’re relatively diversified; both will still have rich pipelines if their COVID-19 vaccines don’t come to fruition. Moderna, as a small, mRNA-focused company, has more at stake in its vaccine trials than the massive biotech conglomerate that is AstraZeneca — but both could see substantial boosts in share price if their vaccine candidates are approved. Ultimately, however, biotech investing without a detailed understanding of the clinical trial process — and the data it produces — is akin to gambling. In order to spot the difference between winners and losers before the rest of the market, you need to be a doctor or scientist... or be in contact with a few of them. [Topline Trader]( provides that biotech investing research bench, so you don’t have to hang out at a medical school to get accurate insights. Editor Jason Stutman employs a team of doctors and biotech researchers to screen drug candidates, and he has helped subscribers win substantial gains on early-stage drug companies. [Click here to learn more](. Until next time, [Monica Savaglia] Samuel Taube Samuel Taube brings years of experience researching ETFs, cryptocurrencies, muni bonds, value stocks, and more to [Wealth Daily](. He has been writing for investment newsletters since 2013 and has penned articles accurately predicting financial market reactions to Brexit, the election of Donald Trump, and more. Samuel holds a degree in economics from the University of Maryland, and his investment approach focuses on finding undervalued assets at every point in the business cycle and then reaping big returns when they recover. To learn more about Samuel, [click here](. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [Smart Cities Won't Be Possible in the U.S. Until December 8, 2020]( [The Truth About the Fed and QE]( [GoodRx Shows Us Its Profitability]( [Good Stories Get Better, Bad Stories Get Worse]( [Battery Day: A Make-or-Break Moment for Tesla]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add newsletter@wealthdaily.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Wealth Daily](, Copyright © 2020, [Angel Publishing LLC](. All rights reserved. 3 E Read Street Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Wealth Daily as well as a link to www.wealthdaily.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Wealth Daily]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. ---------------------------------------------------------------